RU2302245C2 - ПРИМЕНЕНИЕ (11β, 17β)-11-(1,3-БЕНЗОДИОКСОЛ-5-ИЛ)-17-ГИДРОКСИ-17-(1-ПРОПИНИЛ) ЭСТРА-4,9-ДИЕН-3-ОНА ПРИ ЛЕЧЕНИИ БОЛЬШОГО ДЕПРЕССИВНОГО РАССТРОЙСТВА - Google Patents
ПРИМЕНЕНИЕ (11β, 17β)-11-(1,3-БЕНЗОДИОКСОЛ-5-ИЛ)-17-ГИДРОКСИ-17-(1-ПРОПИНИЛ) ЭСТРА-4,9-ДИЕН-3-ОНА ПРИ ЛЕЧЕНИИ БОЛЬШОГО ДЕПРЕССИВНОГО РАССТРОЙСТВА Download PDFInfo
- Publication number
- RU2302245C2 RU2302245C2 RU2004116082/15A RU2004116082A RU2302245C2 RU 2302245 C2 RU2302245 C2 RU 2302245C2 RU 2004116082/15 A RU2004116082/15 A RU 2004116082/15A RU 2004116082 A RU2004116082 A RU 2004116082A RU 2302245 C2 RU2302245 C2 RU 2302245C2
- Authority
- RU
- Russia
- Prior art keywords
- org
- depressive disorder
- estra
- propynyl
- hydroxy
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 44
- 229960000890 hydrocortisone Drugs 0.000 claims description 22
- 208000024714 major depressive disease Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- -1 1,3-benzodioxol-5-yl Chemical group 0.000 claims description 8
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 8
- 239000003862 glucocorticoid Substances 0.000 claims description 8
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 abstract description 25
- 230000001430 anti-depressive effect Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract description 8
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract description 4
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract description 4
- 239000005557 antagonist Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 description 12
- 229940005513 antidepressants Drugs 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960003248 mifepristone Drugs 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 229960002296 paroxetine Drugs 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 102400000739 Corticotropin Human genes 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940127421 Glucocorticoid Synthesis Inhibitors Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002800 anti-glucocorticoid effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204072.1 | 2001-10-26 | ||
| EP01204072 | 2001-10-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004116082A RU2004116082A (ru) | 2005-05-10 |
| RU2302245C2 true RU2302245C2 (ru) | 2007-07-10 |
Family
ID=8181136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116082/15A RU2302245C2 (ru) | 2001-10-26 | 2002-10-21 | ПРИМЕНЕНИЕ (11β, 17β)-11-(1,3-БЕНЗОДИОКСОЛ-5-ИЛ)-17-ГИДРОКСИ-17-(1-ПРОПИНИЛ) ЭСТРА-4,9-ДИЕН-3-ОНА ПРИ ЛЕЧЕНИИ БОЛЬШОГО ДЕПРЕССИВНОГО РАССТРОЙСТВА |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040266863A1 (enExample) |
| EP (2) | EP1441739B1 (enExample) |
| JP (1) | JP4647909B2 (enExample) |
| KR (1) | KR20050038580A (enExample) |
| CN (1) | CN100531738C (enExample) |
| AT (2) | ATE317700T1 (enExample) |
| AU (1) | AU2002348996B2 (enExample) |
| BR (1) | BR0213466A (enExample) |
| CA (1) | CA2463446C (enExample) |
| CY (1) | CY1110173T1 (enExample) |
| DE (2) | DE60209248D1 (enExample) |
| DK (1) | DK1652526T3 (enExample) |
| EC (1) | ECSP045080A (enExample) |
| ES (1) | ES2319563T3 (enExample) |
| HR (1) | HRP20040370B1 (enExample) |
| HU (1) | HUP0500070A3 (enExample) |
| IL (2) | IL161248A0 (enExample) |
| IS (1) | IS2702B (enExample) |
| MX (1) | MXPA04003781A (enExample) |
| NO (1) | NO332978B1 (enExample) |
| NZ (1) | NZ532429A (enExample) |
| PL (1) | PL206687B1 (enExample) |
| PT (1) | PT1652526E (enExample) |
| RU (1) | RU2302245C2 (enExample) |
| WO (1) | WO2003037354A1 (enExample) |
| ZA (1) | ZA200403088B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050080061A1 (en) * | 2003-07-23 | 2005-04-14 | Corcept Therapeutics, Inc. | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| AU2011236053B2 (en) * | 2004-11-19 | 2014-06-26 | Merck Sharpe & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| EP2292269A3 (en) * | 2004-11-19 | 2011-08-10 | N.V. Organon | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| CA2649894A1 (en) * | 2006-05-02 | 2007-11-15 | Corcept Therapeutics, Inc. | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
| WO2012106514A2 (en) * | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| EP2699245A4 (en) * | 2011-04-18 | 2014-12-10 | Pop Test Cortisol Llc | TREATMENT AGAINST HAIR LOSS |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| WO1999017779A1 (en) * | 1997-10-06 | 1999-04-15 | The Board Of Trustees Of Leland Stanford Jr. University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| RU2169153C2 (ru) * | 1994-12-23 | 2001-06-20 | Шеринг Аг | 14,17-c2-мостиковые стероиды и фармацевтический препарат |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| DE19727772A1 (de) * | 1997-06-30 | 1999-01-28 | Forschungszentrum Juelich Gmbh | Magnetflußsensor mit ringförmiger Sonde |
| CN1556709A (zh) * | 2001-03-23 | 2004-12-22 | �Ƹ��� | 使用糖皮质激素受体特效拮抗剂治疗压力症的方法 |
| IL158744A0 (en) * | 2001-05-04 | 2004-05-12 | Corcept Therapeutics Inc | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| MXPA04001893A (es) * | 2001-08-31 | 2005-03-07 | Corcept Therapeutics Inc | Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down. |
-
2002
- 2002-10-21 CA CA2463446A patent/CA2463446C/en not_active Expired - Fee Related
- 2002-10-21 JP JP2003539697A patent/JP4647909B2/ja not_active Expired - Fee Related
- 2002-10-21 CN CNB028210417A patent/CN100531738C/zh not_active Expired - Fee Related
- 2002-10-21 EP EP02781273A patent/EP1441739B1/en not_active Expired - Lifetime
- 2002-10-21 WO PCT/EP2002/011732 patent/WO2003037354A1/en not_active Ceased
- 2002-10-21 AT AT02781273T patent/ATE317700T1/de active
- 2002-10-21 HU HU0500070A patent/HUP0500070A3/hu unknown
- 2002-10-21 AT AT06101005T patent/ATE420649T1/de active
- 2002-10-21 PT PT06101005T patent/PT1652526E/pt unknown
- 2002-10-21 DE DE60209248T patent/DE60209248D1/de not_active Expired - Lifetime
- 2002-10-21 BR BR0213466-7A patent/BR0213466A/pt not_active IP Right Cessation
- 2002-10-21 EP EP06101005A patent/EP1652526B1/en not_active Expired - Lifetime
- 2002-10-21 DE DE60230936T patent/DE60230936D1/de not_active Expired - Lifetime
- 2002-10-21 NZ NZ532429A patent/NZ532429A/en not_active IP Right Cessation
- 2002-10-21 RU RU2004116082/15A patent/RU2302245C2/ru not_active IP Right Cessation
- 2002-10-21 US US10/493,981 patent/US20040266863A1/en not_active Abandoned
- 2002-10-21 MX MXPA04003781A patent/MXPA04003781A/es active IP Right Grant
- 2002-10-21 HR HRP20040370AA patent/HRP20040370B1/xx not_active IP Right Cessation
- 2002-10-21 ES ES06101005T patent/ES2319563T3/es not_active Expired - Lifetime
- 2002-10-21 KR KR1020047006050A patent/KR20050038580A/ko not_active Ceased
- 2002-10-21 IL IL16124802A patent/IL161248A0/xx unknown
- 2002-10-21 PL PL369261A patent/PL206687B1/pl not_active IP Right Cessation
- 2002-10-21 AU AU2002348996A patent/AU2002348996B2/en not_active Ceased
- 2002-10-21 DK DK06101005T patent/DK1652526T3/da active
-
2004
- 2004-03-31 IS IS7204A patent/IS2702B/is unknown
- 2004-04-01 IL IL161248A patent/IL161248A/en not_active IP Right Cessation
- 2004-04-22 ZA ZA200403088A patent/ZA200403088B/en unknown
- 2004-04-23 EC EC2004005080A patent/ECSP045080A/es unknown
- 2004-04-23 NO NO20041651A patent/NO332978B1/no not_active IP Right Cessation
-
2009
- 2009-02-02 CY CY20091100116T patent/CY1110173T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| RU2169153C2 (ru) * | 1994-12-23 | 2001-06-20 | Шеринг Аг | 14,17-c2-мостиковые стероиды и фармацевтический препарат |
| WO1999017779A1 (en) * | 1997-10-06 | 1999-04-15 | The Board Of Trustees Of Leland Stanford Jr. University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
Non-Patent Citations (1)
| Title |
|---|
| ХОЛОДОВ Л.Е. и др. Клиническая фармакокинетика. - М.: Медицина, 1985, с.275 реферат Entrez PubMed: Murphy B.E. et al. Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry. 1998 Apr; 43(3): 279-86. [on line] PMID: 9561317 [найдено 22.06.2006]. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nieman et al. | Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486 | |
| GAILLARD et al. | RU 486 inhibits peripheral effects of glucocorticoids in humans | |
| US20250281504A1 (en) | Method for improving insulin insensitivity | |
| EP2078032B1 (en) | Compositions and methods for suppressing endometrial proliferation | |
| JPH10511378A (ja) | 女性の避妊のための共通使用のためのプロゲステロン拮抗及び抗エストロゲン作用を有する化合物 | |
| Rapkin et al. | Oral contraceptives and neuroactive steroids | |
| RU2302245C2 (ru) | ПРИМЕНЕНИЕ (11β, 17β)-11-(1,3-БЕНЗОДИОКСОЛ-5-ИЛ)-17-ГИДРОКСИ-17-(1-ПРОПИНИЛ) ЭСТРА-4,9-ДИЕН-3-ОНА ПРИ ЛЕЧЕНИИ БОЛЬШОГО ДЕПРЕССИВНОГО РАССТРОЙСТВА | |
| US8193172B2 (en) | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists | |
| AU2002348996A1 (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder | |
| Holdaway et al. | Cyproterone acetate as initial treatment and maintenance therapy for hirsutism | |
| HK1087357B (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder | |
| CN1151792C (zh) | 抗雌激素在制备男性节育药物中的应用 | |
| Opoku et al. | Role of the antiglucocorticoid RU 486 in the prevention of steroid-induced hypertension | |
| Lobo | Cardiovascular disease in women: Influence of hormonal replacement therapy | |
| Burger et al. | The future of hormone replacement therapy | |
| MacLennan et al. | Endocrine and Metabolic Effects of Drugs and Hormonal/Endocrine Manipulation of Non-endocrine Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20110718 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141022 |